Thrombosis may occur with immune globulin intravenous (IGIV) products, including octagam 5% and 10% liquid preparations. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.
Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients with IGIV products, including octagam 5% and 10% liquid preparations. Renal dysfunction and acute renal failure occur more commonly with IGIV products containing sucrose. Octagam 5% and 10% liquid preparations do not contain sucrose.
For patients at risk of thrombosis, renal dysfunction, or acute renal failure administer octagam 5% or 10% liquid preparations at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
Octagam 5% and 10% are made from human plasma and may contain infectious agents, eg, viruses and, theoretically, the Creutzfeldt-Jakob disease agent.
Octagam 5% and 10% contain maltose, a disaccharide, which is derived from corn. Patients known to have corn allergies should avoid using octagam. Falsely elevated blood glucose readings may occur during and after the infusion of octagam with some glucometer and test strip systems.
Please see octagam 5% full Prescribing Information. Please see octagam 10% full Prescribing Information.
